Teva

Teva is one of the large manufacturers of generic medicines, the copies that reach the market after a brand-name drug's exclusivity runs out. This library files the company as tevapharm, which is the id on the FTC's Endo matter. A different id, teva, is not this profile.

The FTC's case concerned pay-for-delay settlements around Endo's Lidoderm patch, a medicated patch for pain. In a pay-for-delay deal the brand-name company pays, or otherwise compensates, a generic company to wait. The generic stays off the market. The brand keeps the price that a launch would have undercut. Teva was on the generic side of that matter and settled. Watson, the other generic name in the file, later became part of the same corporate family. At the time of the conduct they are separate respondents.

Library status is settled. No dollar amount is stated. Patients and insurers are the people who keep paying the brand price during the delay. The settlement is the outcome this library records, not a trial judgment spelling out a number.

Lidoderm, Endo's pain patch, is the product the FTC put at the center of the case.

Pay-for-delay is compensation for a generic to postpone entry, not an ordinary patent license with no payment for time.

This id is tevapharm. The settlement includes the generic side of the Endo matter.

A patient using the brand patch, and the insurer or public program paying for it, bore the price that a launched generic would have cut.

Pharmacies that would have substituted a generic at the counter could not substitute a product that had agreed to wait.